皓元医药
(688131)
| 流通市值：70.91亿 | | | 总市值：72.55亿 |
| 流通股本：2.06亿 | | | 总股本：2.11亿 |
| 报告期 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,270,177,811.5 | 1,619,063,344.9 | 1,055,549,087.12 | 504,874,103.59 |
| 营业收入 | 2,270,177,811.5 | 1,619,063,344.9 | 1,055,549,087.12 | 504,874,103.59 |
| 二、营业总成本 | 1,900,882,004.66 | 1,383,328,088.18 | 919,361,955.83 | 465,236,626.83 |
| 营业成本 | 1,181,279,071.54 | 848,692,363.99 | 576,595,146.66 | 298,884,459.07 |
| 税金及附加 | 13,251,425.49 | 8,711,014.25 | 4,886,237.81 | 2,215,816.05 |
| 销售费用 | 209,908,171.73 | 153,373,226.19 | 97,504,233.7 | 43,702,221.81 |
| 管理费用 | 234,994,900.01 | 175,472,795 | 114,640,604.22 | 57,367,597.11 |
| 研发费用 | 226,932,038.19 | 172,412,405.7 | 112,161,480.92 | 53,593,858.98 |
| 财务费用 | 34,516,397.7 | 24,666,283.05 | 13,574,252.52 | 9,472,673.81 |
| 其中:利息费用 | 31,326,271.51 | 21,690,759.65 | 14,232,513.05 | 6,725,881.87 |
| 其中:利息收入 | 7,482,216.02 | 4,953,820.59 | 3,266,724.17 | 1,768,224.98 |
| 加:公允价值变动收益 | 150,068.49 | - | - | - |
| 加:投资收益 | -13,757,656.87 | -5,034,621.27 | -5,245,231.45 | -2,138,700.84 |
| 资产处置收益 | -567,191.03 | -91,866.73 | -30,736.19 | 4,147.86 |
| 资产减值损失(新) | -131,359,593.72 | -77,892,250.97 | -49,903,371.19 | -22,127,152.32 |
| 信用减值损失(新) | -16,324,015.96 | -13,545,184.25 | -8,343,554.85 | -2,425,005.66 |
| 其他收益 | 29,379,959.17 | 18,589,528.22 | 5,812,609.17 | 3,643,034.56 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 236,817,376.92 | 157,760,861.72 | 78,476,846.78 | 16,593,800.36 |
| 加:营业外收入 | 2,352,504.76 | 457,098.15 | 310,187.98 | 129,653.98 |
| 减:营业外支出 | 814,600.33 | 385,253.44 | 146,192.96 | 23,324.83 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 238,355,281.35 | 157,832,706.43 | 78,640,841.8 | 16,700,129.51 |
| 减:所得税费用 | 40,425,246.77 | 17,053,051.02 | 9,721,948.3 | 163,959.67 |
| 六、净利润 | 197,930,034.58 | 140,779,655.41 | 68,918,893.5 | 16,536,169.84 |
| 持续经营净利润 | 197,930,034.58 | 140,779,655.41 | 68,918,893.5 | 16,536,169.84 |
| 归属于母公司股东的净利润 | 201,590,085.66 | 143,347,970.22 | 70,407,685.66 | 16,757,351.46 |
| 少数股东损益 | -3,660,051.08 | -2,568,314.81 | -1,488,792.16 | -221,181.62 |
| (一)基本每股收益 | 0.96 | 0.68 | 0.33 | 0.11 |
| (二)稀释每股收益 | 0.96 | 0.68 | 0.33 | 0.11 |
| 八、其他综合收益 | 22,673,517.39 | 14,035,099.29 | 12,837,511.63 | 347,032.14 |
| 归属于母公司股东的其他综合收益 | 22,673,517.39 | 14,035,099.29 | 12,837,511.63 | 347,032.14 |
| 九、综合收益总额 | 220,603,551.97 | 154,814,754.7 | 81,756,405.13 | 16,883,201.98 |
| 归属于母公司股东的综合收益总额 | 224,263,603.05 | 157,383,069.51 | 83,245,197.29 | 17,104,383.6 |
| 归属于少数股东的综合收益总额 | -3,660,051.08 | -2,568,314.81 | -1,488,792.16 | -221,181.62 |
| 公告日期 | 2025-03-28 | 2024-10-30 | 2024-08-29 | 2024-04-30 |
| 审计意见(境内) | 标准无保留意见 | | | |